Mereo BioPharma Reports Q3 Revenue of $800,000

Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI)Ongoing FDA interactions in collaboration with Sentynl Therapeutics to refine Phase 3 trial design for alvelestat in alpha-1 antitrypsin deficiency-associated lun…

Mereo BioPharma reported a third-quarter 2026 net loss of $5.9 million, narrowing from $7.0 million a year earlier, while revenue was $0.8 million. Cash and cash equivalents totaled $26.1 million at September 30, 2026, which the company expects to fund operations into late 2027. The company also re…